OVs improve cancer immunotherapy by reprogramming TMEDecember 08, 2023 - Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Immunotherapies using immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy have achieved successful results against several types of human tumors, particularly hematological malignancies. However, their clinical results for the treatment of solid tumors remain poor and unsatisfactory. The immunosuppressive tumor microenvironment (TME) plays an important role by interfering with intratumoral T-cell infiltration, promoting effector T-cell exhaustion, upregulating inhibitory molecules, inducing hypoxia, and so on.
Oncolytic virotherapy (OV) contributes to the reprogramming of the TME, thus synergizing the functional effects of current ICIs and CAR T-cell therapy to overcome resistant barriers in solid tumors.
While other OV companies are theorizing on their prospects, ONCY has CONFIRMED that pelareorep is able to remodel the TME for the effective administration of CPI therapy.
https://pubmed.ncbi.nlm.nih.gov/38062315/